

# Cervical Dystonia Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

<https://marketpublishers.com/r/C574AE3FED6EN.html>

Date: December 2017

Pages: 190

Price: US\$ 4,400.00 (Single User License)

ID: C574AE3FED6EN

## Abstracts

### Cervical Dystonia Management Market

Cervical dystonia, also known as spasmodic torticollis, rare neurological disorder that originates in the brain. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect the quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood. The cause of cervical dystonia is unknown, although a genetic susceptibility is thought to underlie some cases.

The major driving factors for the market for cervical dystonia market is increase in aging population across the globe. Females are more likely to be get affected by cervical dystonia. Besides this increase in treatment for cervical dystonia and improvement in infrastructure provided fuel for the growth of the market. Furthermore, low and increase in cost of treatment is the major cause for restraining the growth of cervical dystonia market.

Cervical Dystonia Management Market segmented on the basis of cervical dystonia type, route of administration, drug class, distribution channel, and region.

Based on the route of administration, it is segmented as:

Oral

Intravenous

Based on the drug class, it is segmented as:

Dopaminergic drugs

Anti-cholinergic drugs

GABA Agonists

Anti Convulsants

Based on the distribution channel, it is segmented as:

Hospital pharmacies

Retail pharmacies

Others

According to the Association of neurological American Surgeons about 250,000 people are having cervical dystonia every year. According to National organization for rare diseases (NORD) it is anticipated that around 60,000 individuals in US are suffering with cervical dystonia

On a regional basis, global cervical dystonia market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The market is dominated by North America due to developed infrastructure, governmental initiatives, and increase in demand for the better treatment of cervical dystonia driving factor in North America. Furthermore, increase in aging population in Canada fuelling the growth of North America cervical dystonia market. Europe and Asia-Pacific accounts to have significant market share. However, Asia-Pacific expected to dominate the market in the forecast period due to continuous development and increase in cervical dystonia treatment procedures. Furthermore, large patient pool in Asia-Pacific region contributes significant growth for cervical dystonia market.

Some of the players in cervical dystonia management market are ALLERGAN (Ireland), US WorldMeds (U.S.), Ipsen (France), Addex Therapeutics (Switzerland), and Revance Therapeutics Inc. (U.S.)

In March, 2017, Ipsen Biopharmaceuticals Inc., the Canadian affiliate of Ipsen has received Health Canada approval for DYSPORE THERAPEUTIC™ (abobotulinumtoxinA)

to treat cervical dystonia.

In 2010, Merz Pharmaceuticals received USFDA approval fo Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET INTRODUCTION**

2.1. Global Cervical Dystonia Management Market – Taxonomy

2.2. Global Cervical Dystonia Management Market –Definitions

2.2.1. Route of Administration

2.2.2. Drug Class

2.2.3. Distribution Channel

### **3. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET DYNAMICS**

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Cervical Dystonia Management Market Dynamic Factors - Impact Analysis

3.6. Global Cervical Dystonia Management Market – Regulations

3.6.1. U.S.

3.6.2. Europe

3.7. Global Cervical Dystonia Management Market –Trends

### **4. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023**

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

### **5. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

5.1. Oral

5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

## 5.2. Intravenous

- 5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.2.3. Market Opportunity Analysis

## **6. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023**

### 6.1. Dopaminergic drugs

- 6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.1.3. Market Opportunity Analysis

### 6.2. Anti-cholinergic drugs

- 6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.2.3. Market Opportunity Analysis

### 6.3. GABA Agonists

- 6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.3.3. Market Opportunity Analysis

### 6.4. Anti Convulsants

- 6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.4.3. Market Opportunity Analysis

## **7. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023**

### 7.1. Hospital Pharmacies

- 7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.1.3. Market Opportunity Analysis

### 7.2. Retail Pharmacies

- 7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.2.3. Market Opportunity Analysis

### 7.3. Others

- 7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

### 7.3.3. Market Opportunity Analysis

## **8. GLOBAL CERVICAL DYSTONIA MANAGEMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

### 8.1. North America

8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.1.3. Market Opportunity Analysis

### 8.2. Europe

8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.2.3. Market Opportunity Analysis

### 8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.3.3. Market Opportunity Analysis

### 8.4. Latin America

8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

### 8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

### 8.6. Global Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Region, 2017 – 2023

## **9. NORTH AMERICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

### 9.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1. Oral

9.1.2. Intravenous

### 9.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Dopaminergic drugs

9.2.2. Anti-cholinergic drugs

9.2.3. GABA Agonists

9.2.4. Anti Convulsants

9.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.3.1. Hospital pharmacies

9.3.2. Retail pharmacies

9.3.3. Others

9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.4.1. U.S.

9.4.2. Canada

9.5. North America Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023

9.6. North America Cervical Dystonia Management Market Dynamics – Trends

## **10. EUROPE CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

10.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1. Oral

10.1.2. Intravenous

10.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Dopaminergic drugs

10.2.2. Anti-cholinergic drugs

10.2.3. GABA Agonists

10.2.4. Anti Convulsants

10.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.3.1. Hospital pharmacies

10.3.2. Retail pharmacies

10.3.3. Others

10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.4.1. Germany

10.4.2. UK

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Poland

10.4.8. Rest of Europe

10.5. Europe Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023

10.6. Europe Cervical Dystonia Management Market Dynamics – Trends

## **11. ASIA-PACIFIC CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

11.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1. Oral

11.1.2. Intravenous

11.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Dopaminergic drugs

11.2.2. Anti-cholinergic drugs

11.2.3. GABA Agonists

11.2.4. Anti Convulsants

11.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.3.1. Hospital pharmacies

11.3.2. Retail pharmacies

11.3.3. Others

11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.4.1. Japan

11.4.2. China

11.4.3. India

11.4.4. ASEAN

11.4.5. Australia & New Zealand

11.4.6. Rest of Asia-Pacific

11.5. Asia-Pacific Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023

11.6. Asia-Pacific Cervical Dystonia Management Market Dynamics – Trends

## **12. LATIN AMERICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS,**



**2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

12.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1. Oral

12.1.2. Intravenous

12.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Dopaminergic drugs

12.2.2. Anti-cholinergic drugs

12.2.3. GABA Agonists

12.2.4. Anti Convulsants

12.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.3.1. Hospital pharmacies

12.3.2. Retail pharmacies

12.3.3. Others

12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Argentina

12.4.4. Venezuela

12.4.5. Rest of Latin America

12.5. Latin America Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023

12.6. Latin America Cervical Dystonia Management Market Dynamics – Trends

**13. MIDDLE EAST AND AFRICA CERVICAL DYSTONIA MANAGEMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)**

13.1. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1. Oral

13.1.2. Intravenous

13.2. Drug Class Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.2.1. Dopaminergic drugs

- 13.2.2. Anti-cholinergic drugs
- 13.2.3. GABA Agonists
- 13.2.4. Anti Convulsants
- 13.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  - 13.3.1. Hospital pharmacies
  - 13.3.2. Retail pharmacies
  - 13.3.3. Others
- 13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  - 13.4.1. Gulf Cooperation Council (GCC) Countries
  - 13.4.2. Israel
  - 13.4.3. South Africa
  - 13.4.4. Rest of MEA
- 13.5. MEA Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2017 – 2023
- 13.6. MEA Cervical Dystonia Management Market Dynamics – Trends

## **14. COMPETITION LANDSCAPE**

- 14.1. Strategic Dashboard of Top Market Players
- 14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  - 14.2.1. Ashland Inc.(U.S.)
  - 14.2.2. AkzoNobel (Netherlands)
  - 14.2.3. The DOW Chemical Company (U.S.)
  - 14.2.4. Archer Daniels Midland Company(U.S.)
  - 14.2.5. Associated British Foods PLC (UK)
  - 14.2.6. Colorcon, Inc.(U.S.)
  - 14.2.7. BASF SE(Germany)
  - 14.2.8. Evonik Industries AG (Germany)
  - 14.2.9. Innophos Holdings Inc. (U.S.)
  - 14.2.10. J.M. Huber Corporation (U.S.)
  - 14.2.11. FMC Corporation (U.S.)
  - 14.2.12. Roquette Group (France)
  - 14.2.13. Croda International PLC (UK)
  - 14.2.14. Merck KGaA (Germany)
  - 14.2.15. Lubrizol Corporation (U.S.)

## 15. RESEARCH METHODOLOGY

## 16. KEY ASSUMPTIONS AND ACRONYMS

## I would like to order

Product name: Cervical Dystonia Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Product link: <https://marketpublishers.com/r/C574AE3FED6EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C574AE3FED6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

